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Summary  Numerous  epidemiological  studies  have  demonstrated  the  atheroprotective  roles
of high  density  lipoproteins  (HDL),  so  that  HDL  is  established  as  an  independent  negative  risk
factor. The  protective  effect  of  HDL  against  atherosclerosis  is  mainly  attributed  to  their  capacity
to bring  peripheral  excess  cholesterol  back  to  the  liver  for  further  elimination  into  the  bile.Mimetic  peptides;
ApoA-I  transcription
In addition,  HDL  can  exert  other  protective  functions  on  the  vascular  wall,  through  their  anti-
inﬂammatory,  antioxidant,  antithrombotic  and  cytoprotective  properties.  HDL-targeted  therapy
is thus  an  innovative  approach  against  cardiovascular  risk  and  atherosclerosis.  These  pleiotropic
atheroprotective  properties  of  HDL  have  led  experts  to  believe  that  ‘‘HDL-related  therapies’’
represent  the  most  promising  next  step  in  ﬁghting  against  atherosclerosis.  However,  because  of
Abbreviations: ABCA1, Adenosine triphosphate binding cassette A1; ABCG1, Adenosine triphosphate binding cassette G1; apo, Apolipopro-
tein; ATP, Adenosine triphosphate; CETP, Cholesteryl ester transfer protein; CVD, Cardiovascular disease; HDL, High-density lipoprotein;
HDL-C, High-density lipoprotein cholesterol; LCAT, Lecithin cholesterol acyl transferase; LDL, Low-density lipoprotein; LDL-C, Low-density
lipoprotein cholesterol; LXR, Liver X receptor; P2Y13, Purinergic receptor 13; PPAR, Peroxisome proliferator-activated receptor; RCT, Reverse
cholesterol transport; SR-BI, Scavenger receptor class B type I; VLDL, Very-low-density lipoprotein.
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the  heterogeneity  of  HDL  functions,  targeting  HDL  is  not  a  simple  task  and  HDL  therapies  that
lower cardiovascular  risk  are  NOT  yet  available.  In  this  paper,  an  overview  is  presented  about
the therapeutic  strategies  currently  under  consideration  to  raise  HDL  levels  and/or  functions.
Recently,  clinical  trials  of  drugs  targeting  HDL-C  levels  have  disappointingly  failed,  suggesting
that HDL  functions  through  speciﬁc  mechanisms  should  be  targeted  rather  than  increasing  per
se HDL  levels.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Le  rôle  athéroprotecteur  des  lipoprotéines  de  haute  densité  (HDL)  est  maintenant
largement  démontré  par  les  études  épidémiologiques.  Cet  effet  bénéﬁque  est  principale-
ment attribué  à  la  fonction  des  HDL  dans  le  transporteur  retour  du  cholestérol,  des  cellules
périphériques,  notamment  les  macrophages  de  la  paroi  artérielle,  vers  le  foie,  où  il  est
ensuite éliminé  via  les  voies  biliaires.  En  outre,  a  été  démontré  que  les  HDL  possèdent  de
nombreux  effets  pléïotropes  telles  que  des  activités  anti-inﬂammatoires,  anti-oxydantes,  anti-
thrombotiques  ou  cyto-protectrices.  Cibler  spéciﬁquement  les  HDL  pourrait  constituer  une
approche  innovante  dans  la  lutte  contre  l’athérosclérose  et  le  risque  cardiovasculaire.  Cepen-
dant, en  raison  de  l’hétérogénéité  de  leurs  fonctions,  cibler  les  HDL  n’est  pas  un  objectif  simple.
Cet article  vise  à  présenter  les  stratégies  actuellement  à  l’étude,  celles-ci  ayant  pour  objectif,
soit d’augmenter  les  concentrations  circulantes  de  HDL-cholestérol  (HDL-C),  soit  de  moduler  les
fonctions  de  ces  lipoprotéines.  Des  essais  cliniques  récents,  portant  sur  des  molécules  augmen-
tant les  taux  de  HDL-C,  n’ont  pas  permis  de  conclure  de  manière  claire  à  une  efﬁcacité  dans  la
réduction  du  risque  cardiovasculaire.  Cela  semble  donc  suggérer  que  ce  sont  les  fonctions  des
HDL qui  devraient  être  ciblées  plutôt  que  simplement  l’élévation  de  leur  concentration.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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pholipids  and  free  cholesterol  through  efﬂux  of  cellularackground
ardiovascular  pathologies  are  now  considered  as  the
iggest  scourge  of  our  modern  society;  during  2008,  nearly
0%  of  deaths  worldwide  were  due  to  cardiovascular  diseases
CVDs)  [1].  At  the  origin  of  most  cardiovascular  pathologies,
therosclerosis  is  a  deleterious  phenomenon  responsible
or  coronary  artery  diseases,  peripheral  vascular  diseases
nd  strokes.  This  inﬂammatory  process  is  characterized  by
lteration  of  the  arterial  wall,  followed  by  lipid  inﬁltration
eading  to  thickening  of  the  atheroma  plaque  and  then,  ulti-
ately,  to  its  rupture  with  the  formation  of  a  thrombus.
holesterol  deposit  is  crucial  and  two  main  lipoproteins  are
ble  to  transport  cholesterol  in  the  plasma:  while  increased
ow-density  lipoprotein  cholesterol  (LDL-C)  concentration  is
mong  the  main  risk  factors  for  CVDs,  high-density  lipopro-
ein  cholesterol  (HDL-C)  concentration  is  inversely  related
o  atherosclerosis  severity.  Therefore,  these  two  varia-
les  are  included  in  systematic  routine  measurements  to
creen  dyslipidaemias  in  the  general  population,  but  also
o  set  therapeutic  objectives.  Lowering  LDL-C,  known  to
e  responsible  for  cholesterol  deposition  in  the  vessel  wall,
as  always  been  one  of  the  most  attractive  targets  of  lipid-
owering  drugs.  Indeed,  statin  therapy  has  a  beneﬁcial  effect
n  the  atherosclerotic  process  and  a  12%  reduction  in  over-
ll  mortality  has  been  observed  for  each  mmol/L  decrease
n  LDL-C  concentration  (40  mg/dL)  [2].  Unfortunately,  the
esidual  risk  remains  important,  which  emphasizes  the  need
o  ﬁnd  new  targets  to  achieve  further  beneﬁts.  Among  all
ossibilities,  raising  HDL-C  concentration  has  appeared  as most  promising  strategy.  Indeed,  epidemiological  stud-
es  have  shown  that  a  0.03  mmol/L  (1  mg/dL)  reduction  in
DL-cholesterol  concentration  is  associated  with  a  2—3%
c
c
encrease  in  cardiovascular  risk  [3].  And,  while  a  concentra-
ion  <  1  mmol/L  (40  mg/dL)  is  considered  as  an  independent
isk  factor  for  CVD,  it  has  recently  been  shown  that  33%
f  men  and  40%  of  women  treated  for  dyslipidaemia  in
urope  display  low  concentrations  of  HDL-C  [4].  A  low  HDL-C
oncentration  is  therefore  very  common  and  strategies  aim-
ng  at  raising  the  plasma  concentration  could  be  promising.
n  the  ﬁrst  part  of  this  review,  we  will  focus  on  the  different
rotective  effects  of  HDL  before  addressing  treatments  that
re  currently  used  or  under  development.
igh-density lipoprotein protective
echanisms
everse cholesterol transport
lassically,  the  main  HDL  atheroprotective  function  is
reverse  cholesterol  transport’  (RCT),  a  process  whereby
xcess  cell  cholesterol  is  taken  up  from  peripheral  (and  vas-
ular  foam)  cells  and  is  delivered  to  the  liver  for  further
limination  into  the  bile.  To  have  a  better  understanding  of
his  process,  it  is  important  to  be  reminded  of  the  struc-
ure  of  HDLs:  these  are  nanoparticles  composed  of  a  lipid
oiety  (free  and  esteriﬁed  cholesterol,  triglycerides,  phos-
holipids,  lysosphingolipids)  and  a  protein  part,  including
he  major  apolipoprotein  A-I  (apoA-I)  and  various  enzymes,
ach  one  being  responsible  for  numerous  beneﬁcial  effects.
rieﬂy,  after  synthesis  by  the  liver,  apoA-I  acquires  phos-holesterol  by  active  (adenosine  triphosphate  [ATP]  binding
assette  A1  and  G1  [ABCA1,  ABCG1])  and  passive  (scav-
nger  receptor  class  B  type  I [SR-BI])  transporters,  to  form
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pre- HDL.  Then,  several  enzymes  carried  by  HDL  itself
lead  to  the  formation  of  mature  HDL.  Lecithin  cholesterol
acyl  transferase  (LCAT)  esteriﬁes  free  cholesterol,  leading
to  migration  of  esteriﬁed  cholesterol  into  the  particle  core,
generating  a  continuous  gradient  of  free  cholesterol  from
cells  towards  HDL.  After  plasma  remodelling,  HDL-C  is  taken
up  by  the  liver  through  SR-BI  and  is  eliminated  into  the  bile
as  free  cholesterol  or  as  biliary  acids  after  metabolism.
Another  putative  pathway  involved  in  RCT  has  also  been
evoked.  Demonstrated  in  mice,  it  is  responsible  for  the
uptake  of  the  whole  HDL  particle  and  involves  activation
of  the  membrane  ecto-F1-ATPase  by  apoA-I  [5].  The  gener-
ated  adenosine  diphosphate  further  activates  the  purinergic
receptor  P2Y13,  which  in  turn  stimulates  endocytosis  of  the
entire  HDL  particle  [6].  Besides  this  general  process,  an
alternate  route  exists  in  humans  for  the  delivery  of  HDL-
C  back  to  the  liver,  involving  cholesteryl  ester  transfer
protein  (CETP);  this  pathway  is  quantitatively  important
in  normolipaemic  conditions.  CETP  is  combined  with  HDL
lipoprotein  and  mediates  transfer  of  esteriﬁed  cholesterol
towards  very-low-density  lipoprotein  (VLDL)  and  LDL  in
exchange  for  triglycerides.  This  transfer  protein  is  there-
fore  responsible  for  a  decrease  in  HDL-C  concentration  but
also  accounts  for  an  enrichment  of  LDL  particles  in  choles-
terol,  allowing  cholesterol  elimination  by  the  liver  through
the  LDL  receptor.  This  indirect  route  that  is  quantitatively
important  in  humans  is  absent  in  rodents,  which  questions
the  relevance  of  murine  models  for  studies  on  lipoprotein
metabolism.
The  whole  RCT  process  is  therefore  physiologically  impor-
tant  as  it  allows  removal  of  excess  cholesterol  from  the
artery  wall  and  from  atherosclerotic  plaques.
a
t
o
b
Figure 1. Pleiotropic protective effects of high-density lipoprotein (H
HDL components or mechanisms responsible for these biological effect
associated death promoter; BAX: Bcl-2-associated X protein; ICAM: interc
oxide; PAF-AH: platelet-activating factor-acetyl hydrolase; S1P: sphingo
receptor class B type I; VCAM: vascular cellular adhesion molecule.py  603
ther atheroprotective effects of high-density
ipoprotein
eyond  this  main  atheroprotective  mechanism,  HDL  exerts
leiotropic  functions  that  protect  against  atherosclerosis
Fig.  1).  Indeed,  as  detailed  in  different  reviews  [7,8],
DL  can  protect  endothelium  by  different  mechanisms:  by
timulating  endothelial  cell  nitrite  oxide  and  prostacyclin
roduction,  HDLs  promote  better  regulation  of  vascular
tructure  and  tone,  and  thus  display  antithrombotic  and
ntiaggregating  properties  [4]. Sphingosine-1-phosphate,
 major  lysosphingolipid  associated  with  HDL  particles,
lso  promotes  endothelial  survival  via  activation  of  its
peciﬁc  receptor.  HDLs  are  also  able  to  decrease  endothe-
ial  apoptosis  induced  by  tumour  necrosis  factor-  and
rowth  factor  deprivation  by  several  mechanisms  and,
articularly,  through  pathways  triggered  by  SR-BI  activa-
ion,  involving  proapoptotic  factors  Bcl-2-associated  death
romoter  and  Bcl-2-associated  X  protein  [4]  or  by  apoA-I-
ediated  ecto-F1-ATPase  activation  [9].  Furthermore,  HDLs
resent  potent  antioxidative  properties  due  to  numerous
nzymes  carried  by  these  lipoproteins,  such  as  paraoxo-
ase,  platelet-activating  factor-acetyl  hydrolase,  LCAT  or
lutathione  selenoperoxidase,  which  degrade  oxidized  lipids
nd  therefore  prevent  LDL  oxidation,  which  is  a  key  deter-
inant  of  atherogenesis.  Apolipoproteins  (A-I,  A-II,  A-IV,  E
r  J)  also  display  antioxidative  properties  and  also  have
n  anti-inﬂammatory  impact.  Moreover,  HDLs  exhibit  an
nti-infectious  role  against  bacteria  and  parasites.  They  pro-
ect  against  endotoxaemia  by  accelerating  bile  clearance
f  gram-negative  bacteria  due  to  their  binding  to  mem-
rane  lipopolysaccharides,  but  they  also  show  speciﬁc  lytic
and F1-ATPase
DL). Green text indicates pleiotropic effects. Red text indicates
s. Apo: apolipoprotein; ATP: adenosine triphosphate; BAD: Bcl-2-
ellular adhesion molecule; LDL: low-density lipoprotein; NO: nitric
sine-1-phosphate; SAA: serum amyloid A protein; SR-BI: scavenger
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ctivity  against  Trypanosoma  brucei  brucei, the  sleeping
ickness  parasite  [10].  In  addition,  HDLs  seem  to  be  impor-
ant  in  cellular  immunity,  through  macrophage  expression
f  inﬂammatory  chemokines,  such  as  monocyte  chemoat-
ractant  protein-1.  HDLs  also  promote  humoral  immunity  by
odulating  activation  of  the  complement  system  [11].
igh-density lipoprotein under inﬂammatory
onditions
DLs  are  complex  particles,  which  are  continuously  remod-
lled.  Systemic  inﬂammation  associated  with  oxidative
tress  induces  structural  and  compositional  modiﬁcations.
hese  abnormal  HDLs  are  considered  dysfunctional,  with
oss  of  their  normal  properties.  Indeed,  it  has  been  shown
hat  acute  phase  proteins,  such  as  serum  amyloid  A,  can
isplace  apoA-I  from  HDL,  causing  a  negative  impact  on
holesterol  efﬂux  capacity.  Modiﬁcation  of  HDL  composition
s  also  deleterious  because  of  enrichment  in  triglycerides
t  the  expense  of  cholesterol  esters.  Finally,  a  decrease  in
ntioxidative  properties  is  related  to  decreased  activities
f  paraoxonase,  platelet-activating  factor-acetyl  hydro-
ase  and  LCAT  [12].  Furthermore,  phospholipase  A2,  either
ipoprotein  associated  or  secreted,  has  been  involved  in
he  inﬂammatory  reaction  occurring  during  atherogenesis.
DLs,  due  to  their  anti-inﬂammatory  effects,  might  coun-
eract  actions  of  phospholipase  A2.  However,  clinical  trials
sing  speciﬁc  phospholipase  A2  inhibitors  did  not  show  sig-
iﬁcant  effects  on  HDL  or  LDL  concentrations,  as  shown  by
ohler  et  al.  [13].  Hence,  in  HDL  particles,  pro-  and  anti-
nﬂammatory  properties  are  in  subtle  equilibrium  and  some
uthors  have  proposed  an  ‘inﬂammatory  index’  to  quantify
DL  properties.  This  approach  assesses  either  LDL-induced
onocyte  chemotaxis  [14]  or  dichloroﬂuorescein  oxidation
15],  with  and  without  HDL.  A  ratio  between  these  two  con-
itions  allows  separation  into  two  groups:  a  ratio  below  1
ndicates  that  HDLs  are  anti-inﬂammatory  and,  conversely,
 ratio  greater  than  1  indicates  a  proinﬂammatory  proﬁle  for
DL.  In  2003,  a  study  reported  that  this  index  could  be  more
seful  than  a  single  measurement  of  HDL-C  for  evaluating
oronary  artery  patients:  among  26  patients,  77%  presented
n  inﬂammatory  index  above  1,  while  only  11%  had  a  low
DL-C  concentration  [16].  Unfortunately,  these  techniques
ave  not  been  introduced  in  routine  measurements  so  far,
robably  because  of  a  lack  of  standardization.
Modiﬁcation  of  HDL  composition  during  acute  or  chronic
nﬂammation  leads  to  functional  alterations;  this  empha-
izes  the  need  to  evaluate  HDL  composition  and  functions,
ather  than  simple  measurement  of  HDL-C  concentration.
herefore,  therapies  improving  HDL  functionality  could  be
 more  promising  bet  compared  with  therapies  that  only
ncrease  concentration.
harmacological therapies
iacin (nicotinic acid)iacin,  also  known  as  nicotinic  acid  or  vitamin  B3,  is  a  physi-
logical  precursor  of  nicotinamide  adenine  dinucleotide  and
icotinamide  adenine  dinucleotide  phosphate,  two  coen-
ymes  involved  in  oxidoreductive  reactions  and  energy
C
m
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etabolism.  An  inadequate  nutritional  intake  leads  to  pel-
agra,  an  old  disease  characterized  by  dermatitis,  dementia
nd  diarrhoea.  Vitaminic  potential  is  demonstrated  with
illigram  doses,  but  at  a pharmacological  dose  of  approx-
mately  1.5—2  g  per  day,  niacin  is  one  of  the  most  potent
gents  available  for  increasing  HDL-C  concentration.  Niacin
lso  reduces  all  proatherogenic  lipids  and  lipoproteins,
ncluding  total  cholesterol,  triglycerides,  VLDL,  LDL  and
ipoprotein(a).  Different  potential  mechanisms  underlying
he  antidyslipidaemic  effects  of  niacin  have  been  recently
xtensively  reviewed  [17,18]  and  are  summarized  in  Fig.  2
nd  Table  1. Beyond  its  lipid-modifying  activity,  niacin  has
lso  been  shown  to  exert  other  potential  antiatherosclerotic
ffects,  in  part  through  mechanisms  involving  its  receptor
hydroxycarboxylic  acid  receptor  2  [also  called  GPR109A])
n  immune  cells  as  well  as  through  direct  and  indirect
ffects  on  the  vascular  endothelium  [18].  In  accordance  with
hese  pleiotropic  potentially  beneﬁcial  actions  of  niacin  in
VDs,  its  therapeutic  use  has  been  considered  for  decades
n  the  prevention  and  treatment  of  atherosclerosis,  but  neg-
tive  outcomes  of  recent  clinical  trials  —  discussed  below  —
ave  led  to  questions  about  its  efﬁcacy.
Initially,  an  immediate  release  form  of  niacin  was  used,
ut  was  associated  with  frequent  ﬂushes  due  to  activation  of
ydroxycarboxylic  acid  receptor  2  on  epidermal  Langerhans
ells  as  well  on  keratinocytes,  and  subsequent  formation
f  prostaglandins  D2  and  E2.  Different  pharmaceutical  for-
ulations  have  been  developed:  an  extended-release  form
Niaspan®),  which  causes  fewer  ﬂushes  because  of  its  lower
bsorption  rate;  an  extended-release  form  combined  with
aropiprant,  a  prostaglandin  D2 antagonist  (CordaptiveTM,
lso  called  TredaptiveTM);  and  niacin  combined  with  sim-
astatin  (Simcor®) or  lovastatin  (Advicor®).  Two  large
ublicized  clinical  trials  have  been  recently  designed  to
valuate  whether  adding  these  modern  niacin  formulations
o  statin  therapy  provides  incremental  beneﬁt  over  statin
herapy  alone  in  terms  of  cardiovascular  primary  events
n  patients  with  established  CVD:  AIM-HIGH  (Atherosclero-
is  Intervention  in  Metabolic  Syndrome  with  Low  HDL/High
riglycerides  and  Impact  on  Global  Health  Outcomes)  and
PS2-THRIVE  (Heart  Protection  Study  2-Treatment  of  High
ensity  lipoprotein  to  Reduce  the  Incidence  of  Vascular
vents).
AIM-HIGH,  which  compared  the  Niaspan®/simvastatin
ombination  with  simvastatin  alone  in  about  3500  patients
as  stopped  before  the  planned  end  because  of  a  lack  of  car-
iovascular  reducing  effects  and  because  of  a  non-signiﬁcant
rend  towards  an  increase  in  ischaemic  strokes  in  the  treated
roup.  However,  as  explained  by  Nicholls  [19],  several  lim-
tations  may  balance  the  negative  ﬁndings  of  this  study,
ncluding  higher  doses  of  simvastatin  and  greater  use  of  eze-
imibe  (22%  vs.  10%)  in  the  statin  only  arm  compared  with  in
he  statin/niacin  arm,  as  well  as  the  fact  that  the  statin  only
roup  actually  received  a  low  dose  of  niacin  (up  to  200  mg)
o  mimic  ﬂushes  and  did  have  an  increase  in  HDL-C  (+9.8%).
inally,  the  study  was  stopped  after  only  36  months,  which
ight  have  been  too  early  to  observe  beneﬁts  in  patients
ith  baseline  LDL-C  concentrations  of  only  71  mg/dL.
Concerning  HPS2-THRIVE,  which  evaluated  the
ordaptiveTM/statin  combination  versus  statin  alone  in
ore  than  25,600  patients,  the  trial  was  recently  stopped
fter  only  3.9  years  because  of  serious  adverse  events  —  not
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Figure 2. Possible explanations for the effects of nicotinic acid on lipoprotein proﬁle and protective mechanisms. apo: apolipoprotein;
ATP: adenosine triphosphate; CE: cholesterol ester; CETP: cholesteryl ester transfer protein; DGAT: diacylglycerol acyltransferase; HCAR:
L: lo
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detailed  yet  —  in  the  treated  arm.  The  primary  endpoints
(i.e.,  reduction  in  heart  attacks  and  strokes)  were  also  not
met  and  a  statistical  increase  in  non-fatal  side  effects  was
even  reported  in  the  niacin-treated  group  [20].  However,
a  detailed  subgroup  analysis,  especially  of  those  subgroups
most  likely  to  beneﬁt  from  niacin  therapy  (i.e.,  patients
with  low  HDL-C  concentration),  might  yield  more  insight
into  this  trial.  Moreover,  despite  these  disappointing
extended-release  niacin  trials  (AIM-HIGH  and  HPS-THRIVE),
a  recent  meta-analysis  of  11  clinical  trials,  including
AIM-HIGH,  in  9959  subjects,  showed  that  niacin  therapy
was  associated  with  a  signiﬁcant  reduction  in  major  CVD
and  coronary  heart  disease  events  [21],  which  might
partly  rescue  niacin’s  reputation  as  an  effective  preventive
therapy.
In  conclusion,  better  understanding  of  niacin’s  actions
and  targets  might  help  to  better  design  combination  therapy
and  new  treatment  strategies  for  atherosclerosis.
Cholesteryl ester transfer protein inhibitors
Given  the  proatherogenic  potential  of  CETP,  which  favours
transfer  of  cholesterol  from  HDL  to  LDL,  synthetic  inhibitors
were  developed  to  restore  a  favourable  lipoprotein  pro-
ﬁle  by  increasing  HDL-C  concentration  and  lowering  LDL-C
concentration.  Torcetrapib  (Pﬁzer,  New  York,  USA)  was  the
ﬁrst  molecule  to  be  designed  as  an  inhibitor  of  CETP  lipid
transfer  functions.  Evaluated  in  phase  III  (the  ILLUMINATE
study),  its  development  was  stopped  due  to  a  global  over-
all  mortality  in  patients  treated  with  torcetrapib,  although
HDL-C  concentration  had  increased.  Subsequent  analyses
showed  that  this  negative  effect  was  due  to  activation  of
the  renin-angiotensin-aldosterone  system,  increasing  blood
ﬁ
a
c
ww-density lipoprotein; MCP: monocyte chemoattractant protein;
 adhesion molecule; VLDL: very-low-density lipoprotein.
ressure,  but  also  to  direct  vascular  endothelium  toxicity
33].
After  this  failure,  new  drugs  were  still  developed:
alcetrapib  (Hoffman-La  Roche  Inc,  Basel,  Switzerland),
vacetrapib  (Eli  Lilly  and  Co,  Indianapolis,  USA)  and  anace-
rapib  (Merck  &  Co,  Whitehouse  station,  USA).  Concerning
alcetrapib,  several  studies  have  been  scheduled  (dal-
ESSEL  and  dal-PLAQUE),  but  the  phase  III  dal-OUTCOME
tudy  was  stopped  in  May  2012  due  to  a  lack  of  signiﬁcant
esults.  The  safety  of  evacetrapib  has  been  demonstrated  in
 phase  II  study  involving  398  patients  [25]; a  phase  III  study
egan  in  October  2012  to  evaluate  its  efﬁcacy  and  safety
versus  placebo)  in  participants  with  high-risk  vascular  dis-
ase  (the  ACCELERATE  study).  Lastly,  two  phase  III  trials  are
urrently  underway  for  anacetrapib:  the  DEFINE  trial  (Deter-
ining  the  Efﬁcacy  and  Tolerability  of  CETP  Inhibition  with
nacetrapib)  was  completed  by  the  end  2012  and  the  REVEAL
SP-3  TIMI-55  trial  (Randomized  Evaluation  of  the  Effects
f  Anacetrapib  through  Lipid  Modiﬁcation),  which  includes
0,000  coronary  patients  treated  with  statins,  will  end  in
017.
econstituted high-density lipoprotein
ntravenous  administration  of  liposomic  complexes  contain-
ng  human  proapolipoprotein  A-I  (the  secreted  form  of
poA-I)  in  four  patients  with  familial  hypercholesterolaemia
howed  a  >  30%  stimulation  of  faecal  excretion  of  cholesterol
nd  biliary  acids  [34]. This  increase  in  RCT  was  further  con-
rmed  in  the  ﬁrst  clinical  trial  using  puriﬁed  human  apoA-I
nd  synthetic  phospholipids  [35].  Puriﬁed  apoA-I  was  then
ombined  with  soya  phophatidylcholines  and  the  product
as  called  CSL-111.  These  reconstituted  HDLs  were  tested
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n  the  ERASE  trial  (Effect  of  rHDL  on  Atherosclerosis  Safety
nd  Efﬁcacy)  in  patients  with  acute  coronary  syndrome
36].  Although  CSL-111  produced  a  3.4%  volume  reduction
n  the  atherosclerotic  plaque  after  a  weekly  perfusion  over
 month,  its  development  has  been  stopped  because  of  liver
oxicity.  Second  generation  products  have  emerged,  such  as
SL-112  (CSL  Laboratories,  Victoria,  Australia)  and  CER-001
Cerenis  Therapeutics  Labège,  France),  which  are  currently
eing  tested  in  acute  coronary  syndrome  patients  (a  phase  II
tudy)  and  in  patients  with  familial  hypercholesterolaemia
for  CER-001).
In  the  early  1980s,  apoA-I  Milano  was  discovered  in  North-
rn  Italy  (Limone  sul  Garda)  in  three  members  of  a  family
resenting  with  signiﬁcant  hypertriglyceridaemia  associated
ith  low  HDL-C  concentrations  (0.07—0.14  g/L),  without  any
anifestation  of  atherosclerosis  [37].  This  abnormal  apoA-I
iffers  from  the  native  form  by  a  substitution  at  position
73,  where  arginine  is  replaced  by  cysteine,  leading  to
oss  of  stability  and  decreased  afﬁnity  for  lipids,  explaining
he  accelerated  degradation  of  free  apoA-I  by  the  kidneys.
owever,  it  has  since  been  demonstrated  that  this  muta-
ion  allows  formation  of  apoA-I  Milano  homodimers  and  that
his  particular  apoA-I  displays  a  higher  capacity  for  cellu-
ar  cholesterol  efﬂux  and  has  a  potent  antioxidant  activity,
herefore  preventing  phospholipid  oxidation  [38,39].  Recon-
tituted  HDL  containing  apoA-I  Milano  dimers  and  synthetic
hospholipids  (named  ETC-216  and  then  MDCO-216;  The
edicines  Company,  Parsippany,  USA)  have  shown  beneﬁcial
ffects  in  patients  with  acute  coronary  syndrome:  weekly
erfusions  over  5  weeks  led  to  a  4.2%  decrease  in  volume  of
he  atherosclerotic  plaque  [26].
Despite  encouraging  results,  reconstituted  HDL  therapies
ave  not  yet  emerged.  However,  rapid  regression  of  a  condi-
ion  that  has  developed  over  years  was  observed  after  only
 few  injections,  which  indicates  the  potential  value  of  this
herapeutic  approach.
imetic peptides
poA-I  is  a  major  atheroprotective  protein  due  to  its
ntioxidant  properties  and  its  capacity  to  capture  excess
ell  cholesterol,  notably  from  macrophages.  However,  this
olecule  is  difﬁcult  and  expensive  to  produce,  which  has
otivated  the  synthesis  of  smaller  oral  ingestible  apoA-I
imetic  peptides.  Among  them,  synthesis  of  octadecapep-
ides  called  18A  has  emerged;  although  they  do  not  present
ny  homology  with  apoA-I,  they  are  able  to  mimic  its  func-
ional  activity  and  have  identical  binding  capacity.  In  this
amily,  peptides  4F  and  5F  appear  to  be  the  most  effective.
he  4F  peptide  binds  oxidized  phospholipids  with  higher
fﬁnity  than  apoA-I  [40]  and  oral  administration  of  D-4F
eads  to  a  decrease  in  the  HDL  inﬂammatory  index  [41].
he  levorotatory  enantiomer  called  L-4F  (or  APL180;  Novar-
is,  Basel,  Switzerland),  which  is  degraded  in  the  intestine
nd  thus  cannot  be  orally  administered,  has  been  tested  via
ntravenous  infusion  for  7  days  or  via  subcutaneous  injec-
ion  for  28  days.  Unfortunately,  despite  modiﬁcation  of  the
ipoprotein  proﬁle,  the  HDL  inﬂammatory  index  did  not
mprove  and  authors  observed  a  trend  toward  elevated  C-
eactive  protein  [27].
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elipidated high-density lipoprotein
hanks  to  a  selective  delipidation  method  allowing  conver-
ion  of  large  lipidated  HDL  to  lipid-poor  HDL,  RCT  was
ound  to  be  enhanced  [42]. A  clinical  study,  the  LS-001
Lipid  Sciences  Selective  Delipidation  Trial),  has  evaluated
he  effect  of  serial  autologous  infusions  of  delipidated  HDL
n  14  patients  with  acute  coronary  syndrome.  Although  the
esults  showed  its  harmlessness,  no  signiﬁcant  improve-
ent  was  seen  in  atheroma  volume  despite  a  non-signiﬁcant
ecrease  [43].
eroxisome proliferator-activated receptor
gonists ( and  glitazars)
eroxisome  proliferator-activated  receptors  (PPARs)  are
uclear  transcription  receptors  involved  in  lipid  and  carbo-
ydrate  homeostasis;  they  are  composed  of  three  isoforms
,    and  ß/).  After  activation,  PPARs  heterodimerize  with
he  retinoid  X  receptor  and  further  bind  to  a  speciﬁc  DNA
egion  called  peroxisome  proliferator  response  element,
ocalized  on  target  genes.
The  ﬁrst  agonists  synthesized,  commonly  known  as
brates,  targeted  the    isoform,  which  is  mainly  expressed
n  liver,  heart  and  muscle.  After  binding,  expression  of
umerous  genes  is  up-regulated,  including  genes  encod-
ng  apoA-I,  apoA-II,  ABCA1  and  acyl-CoA  synthetase,  the
ast  of  which  promotes  fatty  acid  oxidation.  Other  genes,
uch  as  ﬁbrinogen,  cyclo-oxygenase  2,  vascular  cell  adhe-
ion  molecule  and  C-reactive  protein,  are  down-regulated,
hus  enabling  an  overall  protective  effect.  Indeed,  ﬁbrates
mprove  lipoprotein  plasma  proﬁle  and  insulin  sensitivity,
epress  inﬂammation  and  clotting  and  enhance  vasomotor
eactivity  [28]. As  summarized  by  Chapman,  triglycerides
re  reduced  by  30—50%,  LDL  by  15—20%  and  HDL-C  rises
rom  5%  to  15%  [44]. Many  clinical  studies  have  assessed
he  impact  of  ﬁbrates  on  clinical  outcomes  in  primary  and
econdary  prevention  (the  Helsinki  Heart  Study,  the  VA-HIT
tudy,  the  BIP  study,  the  FIELD  study,  etc.).  Despite  a  34%
eduction  in  major  coronary  events  at  5  years,  as  shown  by
he  Helsinki  Heart  Study  [44],  ﬁbrates  have  failed  to  reduce
verall  mortality  in  the  general  population.  They  are  poten-
ially  useful  in  speciﬁc  populations  and  selective  subgroups:
or  instance,  fenoﬁbrate  and  bezaﬁbrate  could  be  useful  for
iabetes  or  metabolic  syndrome  and  gemﬁbrozil  could  be
seful  for  patients  with  dyslipidaemia  [45].
The    isoform,  highly  expressed  in  adipose  tissue  and
uscle,  regulates  glucose  homeostasis  and  insulin  sen-
itivity,  in  addition  to  its  role  in  lipid  metabolism  and
nﬂammation.  Thus,  agonists  called  glitazones  have  been
esigned  to  be  used  in  type  2  diabetes  mellitus.  Unfortu-
ately,  due  to  side  effects  (bladder  cancer  for  pioglitazone,
ncreased  cardiovascular  risk  for  rosiglitazone  and  periph-
ral  oedema  for  both),  this  family  of  molecules  is  no  longer
arketed  in  France.
Thus,  the  general  idea  was  to  create  dual  agonists  that
re  able  to  impact  lipid  and  carbohydrate  metabolism  by
argeting  the  two  isoforms,    and  .  New  drugs  were
herefore  designed,  called  glitazars,  which  have  posi-
ive  effects  on  lipid  metabolism  due  to  activation  of
PAR-  in  the  liver  and  insulin-sensitizing  effects,  as  a
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consequence  of  PPAR- activation,  making  possible  their
use  in  metabolic  syndrome  [46],  a  condition  associated  with
low  HDL.  Due  to  side  effects  (haematological  disturbance,
serum  creatinine  increase,  etc.)  [45],  most  molecules  were
given  up  on,  except  for  aleglitazar  (Hoffmann-La  Roche
Inc.,  Basel,  Switzerland).  During  a  16-week  administration
period,  its  safety  and  positive  impact  on  lipoprotein  proﬁle
was  shown  in  type  II  diabetics  in  the  phase  II  SYNCHRONY
study  [47].  The  maximum  effect  on  HDL-C  concentration
was  seen  with  a  150  g  dose  (placebo-adjusted  increase
of  20.7%,  13.2—28.2)  and  was  responsible  for  a  greater
effect  than  45  mg  of  pioglitazone.  The  same  dose  led  to  a
decrease  in  triglycerides  (—43.4%,  —27.4  to—59.4)  and  LDL-
C  (—15.5%,  —5.4  to—25.6).  Glycated  haemoglobin  decreased
in  a  dose-dependant  manner.  Furthermore,  according  to
an  investigator  update  from  Roche’s  website,  AleNephro
(a  phase  IIb  study)  has  also  demonstrated  the  renal  safety
of  this  molecule  in  type  II  diabetes  patients  with  stage  3
chronic  kidney  disease.  A  phase  III  study  (AleCardio),  includ-
ing  patients  with  type  2  diabetes  hospitalized  for  acute
coronary  syndrome,  began  in  2009  and  results  are  expected
in  2015.
Other targets
Liver  X  receptor  agonists
Liver  X  receptors  (LXRs)  belong  to  a  nuclear  receptor  fam-
ily  involved  in  lipid  homeostasis.  Activated  by  oxysterols,
derived  from  cholesterol  degradation  or  from  dietary  intake,
LXRs  consist  of  two  isoforms  (  and  ).  While  LXR is  highly
expressed  in  liver,  intestine,  kidney,  spleen  and  adipose
tissue,  LXR is  ubiquitously  expressed,  but  at  lower  con-
centrations.  Considered  as  intracellular  sensors,  they  can
activate  transcription  of  many  genes  involved  in  RCT,  such
as  ABCA1, ABCG1  and  CETP, and,  at  the  same  time,  they
depress  expression  of  genes  involved  in  intestinal  choles-
terol  absorption,  such  as  Niemann-Pick  C1-Like  1  (NPC1L1).
However,  as  LXR also  stimulates  the  synthesis  of  fatty  acids
and  triglycerides  in  the  liver,  its  agonists  have  lipogenic
effects.  This  emphasizes  the  need  to  synthesize  LXR-
speciﬁc  agonists,  which  is  currently  difﬁcult  to  achieve  due
to  a  high  sequence  homology  between  the  two  isoforms
(80%  homology  sequence).  Besides,  a  positive  effect  on  CETP
transcription  was  also  noted,  which  could  confer  fewer  ben-
eﬁcial  effects  in  humans  than  those  observed  in  species
lacking  CETP,  such  as  mice.
Stimulation  of  apolipoprotein  A-I  transcription
RVX-208  (Resverlogix  Corp.,  Calgary,  Canada)  was  the  ﬁrst
bromo  and  extra  terminal  (BET)  bromodomain  (an  epige-
netic  regulator)  inhibitor  to  be  used  in  therapeutics.  This
oral  inducer  of  apoA-I  synthesis  was  ﬁrst  evaluated  over
12  weeks  in  225  patients  from  the  ASSERT  study  (ApoA-I
Synthesis  Stimulation  Evaluation  in  Patients  Requiring  Treat-
ment  for  Coronary  Artery  Disease)  [48].  ApoA-I  changes
did  not  reach  statistical  signiﬁcance,  although  a trend
was  observed,  but  higher  increases  could  require  chronic
treatment.  HDL-C  concentrations  increased  from  3.2%  to
8.3%  according  to  dose  and  transient  elevations  of  liver
transaminases  were  seen.  Two  phase  II  studies  are  under
way:  SUSTAIN  (The  Study  of  Quantitative  Serial  Trends  in
t
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ipids  with  ApoA-I  Stimulation),  which  is  evaluating  its
afety  and  efﬁcacy  on  blood  lipids;  and  ASSURE  (The  ApoA-I
ynthesis  Stimulation  and  Intravascular  Ultrasound  for  Coro-
ary  Atheroma  Regression  Evaluation),  which  is  studying
ts  impact  on  atherosclerotic  plaques.  A  press  release  on
he  Resverlogix  website  (August  28,  2012)  states  that  after
4  weeks  of  treatment  in  the  SUSTAIN  study,  there  was  a
tatistical  increase  in  HDL-C,  apoA-I  and  large  HDL  particle
oncentrations  without  any  further  increase  in  transaminase
oncentrations.  Results  of  the  ASSURE  study  are  expected  in
013.
odulation  of  reverse  cholesterol  transport
ith  the  aim  of  increasing  HDL-C  concentration,  researchers
ried  to  ﬁnd  new  drugs  targeting  HDL  uptake  and  catabolism
y  the  liver.  In  this  regard,  Masson  et  al.  tested  a  novel  SR-BI
nhibitor  —  ITX5061  —  in  mice  and  humans  [29].  The  use  of
TX5061  in  hypertriglyceridaemic  patients  led  to  an  increase
n  HDL-C  concentration  of  about  20%  without  modifying  LDL-
 or  triglyceride  concentrations.  Furthermore,  ITX5061  was
esponsible  for  a  reduction  in  early  atherosclerotic  lesions  in
he  aortic  arch  in  mice  fed  an  atherogenic  diet.  However,  the
eneﬁcial  effect  of  inhibition  of  SR-BI,  which  participates
n  hepatic  HDL-C  uptake  and  cellular  cholesterol  efﬂux,  is
uestionable,  as  this  would  rather  impair  RCT.
onclusion
he  concept  of  HDL-therapy,  considered  as  one  of  the  most
romising  strategies  for  the  treatment  of  atherosclerosis,  is
ot  yet  established  (as  summarized  in  Table  1).  Epidemiolog-
cal  studies  had  given  hope  that  a  simple  increase  in  HDL-C
ould  reduce  cardiovascular  risk.  However,  HDL  metabolism
s  quite  complex  and  is  still  not  completely  understood.  The
ermination  of  the  CETP  inhibitor  dalcetrapib,  the  lack  of
ffect  of  niacin  in  the  AIM-HIGH  and  HPS2-THRIVE  clinical
rials  [19,20]  and  evidence  for  a  lack  of  association  with
ardiovascular  risk  in  genome-wide  association  studies  of
DL  genes  [30]  have  all  raised  questions  about  the  HDL
ypothesis  and  have  cast  many  doubts  about  the  relevance
f  increasing  HDL-C  concentration  per  se.
One  argument  to  explain  the  HDL  controversy  is  that
DL-C  concentration  is  a  poor  measure  for  targeted  inter-
ention.  HDL-C  concentration  is  considered  a  surrogate  for
he  efﬁciency  of  cholesterol  efﬂux  from  tissues.  However,
iven  that  macrophage-derived  cholesterol  represents  only
 minor  proportion  of  the  cholesterol  transported  by  HDL
articles,  this  may  be  an  inadequate  measure.  Moreover,
DL-C  concentration  is  a  static  measurement,  and  does  not
ake  into  account  the  dynamics  of  the  HDL  particle  popula-
ion  and  HDL  functionality,  which  might  differ  depending  on
he  metabolic  status  of  individuals.  For  instance,  patients
ith  type  2  diabetes  display  a  higher  catabolic  rate  of  HDL-
poA-I  [49]  and  HDL  from  coronary  patients  does  not  have
ndothelial  anti-inﬂammatory  effects  [50],  illustrating  the
eed  to  identify  more  precisely  the  patient  subgroups  that
hould  beneﬁt  from  personalized  HDL  therapies.In  this  context,  although  there  is  still  an  urgent  need
o  better  understand  the  molecular  mechanisms  under-
ying  multiple  regulation  downstream  HDL  action,  other
herapeutic  strategies  aiming  to  improve  some  critical  steps
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Table  1  Summary  of  high-density  lipoprotein  therapeutic  options,  targets  and  main  effects.
Drugs  Targets  Positive  impacts  Negative  impacts
Niacin  (nicotinic  acid)  Inhibition  of  DGAT-2  (ﬁnal  enzyme  of
TG  synthesis  in  the  liver)  [17,18]
Plasmatic  TG  concentration  Lack  of  cardiovascular  reducing  effect  in
secondary  prevention  trials  (AIM-HIGH  and
HPS2-THRIVE)  [19,20]  but  a  recent  meta-analysis
involving  11  clinical  trials  showed  a  signiﬁcant
reduction  in  major  cardiovascular  diseases  and
coronary  heart  disease  events  [21]
Activation  of  HCAR-2  (fewer  free  fatty
acids  delivered  by  the  adipocyte)  [18]
Expression  of  the    chain  of  F1-ATPase
on  the  hepatocyte  cell  surface  [17]
Plasma  HDL-C  and  apoA-I
concentrations
CETP  transcription  in  animals  [22]
VCAM-1  and  MCP-1  expression
(mechanism?)  [18]
Anti-inﬂammatory
Fibrinogen  and  PAI-1  expression
(mechanism?)  [23]
Antithrombotic
Activation  of  HCAR-2  (Langerhans  cells
and  macrophages):  prostaglandin  D2  and
E2  synthesis  (activation  of  their
respective  receptors  in  dermal
capillaries)  [18]
Skin  ﬂushes  (dose  related,  poor  compliance)
Inhibitors  of  CETP  Inhibition  of  CETP  (anacetrapib,
dalcetrapib,  evacetrapib,  torcetrapib)
Plasma  HDL-C  concentration
(anacetrapib  and  evacetrapib  >  130%,
torcetrapib  ≈  70%,  dalcetrapib  ≈  30%)
[24]
For  torcetrapib:  increased  blood  pressure  and
aldosterone  production
For  torcetrapib:  increased  blood  pressure  and
aldosterone  production
For  dalcetrapib:  no  signiﬁcant  reduction  in
cardiovascular  adverse  events
Plasma  LDL-C  concentration  [24]
Safety  for  evacetrapib  [25]
Phase  III  anacetrapib  clinical  trials
ongoing
Reconstituted  HDL
(liposomes  with
puriﬁed  apoA-I  or
apoA-I  Milano)
Mimic  HDL  properties  Modiﬁcation  of  lipoprotein  proﬁle
Decrease  in  volume  of
atherosclerotic  plaque  (apoA-I  Milano)
[26]
Second  generation  products
currently  being  tested  in  ACS  and
familial  hypercholesterolaemia
Targeting
 high-density
 lipoproteins:
 U
pdate
 on
 a
 prom
ising
 therapy
 
609
Table  1  (Continued)
Drugs  Targets Positive  impacts Negative  impacts
Mimetic  peptides
(octapeptides)
Mimic  apoA-I  properties Modiﬁcation  of  lipoprotein  proﬁle
[27]
No  modiﬁcation  of  HDL  inﬂammatory  index  [27]
PPAR    and    agonists
(glitazars)
PPAR activation: transcription  of
apoA-I  and  apoA-II, transcription  of
VCAM-1  and  ﬁbrinogen  [28]
PPAR activation  of  genes  involved  in
glucose  homeostasis
Improvement  in  lipoprotein  proﬁle
Insulin-sensitizing  effects
Current  phase  III  aleglitazar  clinical
trial  in  type  2  diabetes
Toxicity  of  ﬁrst  generation  drugs
PPAR    and    agonists
(glitazars)
PPAR activation: transcription  of
apoA-I  and  apoA-II, transcription  of
VCAM-1  and  ﬁbrinogen  [28]
PPAR activation  of  genes  involved  in
glucose  homeostasis
Improvement  in  lipoprotein  proﬁle
Insulin-sensitizing  effects
Current  phase  III  aleglitazar  clinical
trial  in  type  2  diabetes
Toxicity  of  ﬁrst  generation  drugs
LXR  agonists  LXR    and  :  expression  of  genes
involved  in  RCT  and  expression  of  genes
involved  in  intestinal  cholesterol
absorption
Lipogenic  effects
BET  bromodomain
inhibitors
Epigenetic  regulation:  stimulation  of
apoA-I  transcription
apoA-I  and  HDL  concentrations  [29]
Two  phase  II  studies  underway
Modulators  of  reverse
cholesterol  transport
Inhibition  of  SR-BI  (BLT-1,  ITX-5061,
ML278,  ML279)
HDL-C,  no  modiﬁcation  of  LDL  [30]  Hepatic  HDL-C  uptake  could  lead  to
detrimental  accumulation  with  impairment  of
their  functions
Activation  of  P2Y13 (AR-C69931MX,
ct1007900)
Hepatic  HDL-C  uptake  [31]  HDL-C  (?)  could  lead  to  in  pleiotropic
activities  of  HDL
RCT  [31]
Atherosclerosis  regression  in  animal
models  [32]
apo: apolipoprotein; ACS: acute coronary syndrome; ATP: adenosine triphosphate; BET: bromo and extra terminal; CETP: cholesteryl ester transfer protein; DGAT: diacylglycerol acyltrans-
ferase; HCAR: hydroxycarboxylic acid receptor; HDL: high-density lipoprotein; HDL-C: high-density lipoprotein cholesterol; LDL: low-density lipoprotein; LDL-C: low-density lipoprotein
cholesterol; LXR: liver X receptor; MCP: monocyte chemoattractant protein; P2Y13: purinergic receptor 13; PAI: plasminogen activator inhibitor; PPAR: peroxisome proliferator-activated
receptor; RCT: reverse cholesterol transport; SR-BI: scavenger receptor class B type I; TG: triglycerides; VCAM: vascular cell adhesion molecule; VLDL: very-low-density lipoprotein.
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f  HDL  metabolism  and  HDL  pleiotropic  beneﬁcial  func-
ions  (i.e.,  antioxidant,  anti-inﬂammatory)  have  emerged.
or  instance,  among  recent  ﬁndings,  the  newly  discovered
DL  endocytosis  pathway,  involving  ecto-F1-ATPase  and  the
2Y13 receptor,  could  be  an  interesting  target  for  increas-
ng  HDL  liver  uptake  [5,6,31].  Indeed,  ct1007900,  a P2Y13
eceptor  agonist,  has  recently  been  tested  in  animal  models,
emonstrating  potential  beneﬁcial  effects  on  atheroscle-
otic  plaques  [32].
In  conclusion,  the  residual  risk  persisting  under  statin
reatment  means  that  more  research  is  needed  on  potential
herapeutic  approaches  and  that,  despite  numerous  set-
acks,  HDL  should  be  targeted  by  new  drugs  addressing
peciﬁc  mechanisms.
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